Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Updates on tafasitamab for the treatment of DLBCL

Wojciech Jurczak • 11 Jun 2022
EHA 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Bendamustine CAR-T Lenalidomide Polatuzumab vedotin Rituximab Tafasitamab

In this video, Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, talks on tafasitamab for the treatment of diffuse large B-cell lymphoma (DLBCL), highlighting a study which demonstrated the efficacy of patients treated with tafasitamab plus lenalidomide compared to patients treated with polatuzumab vedotin and CAR-T cell therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Wojciech Jurczak

1:35
Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL
Wojciech Jurczak • 10 Jun 2023
3:01
Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCL
Wojciech Jurczak • 10 Jun 2023
1:49
Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL
Wojciech Jurczak • 10 Jun 2023
0:55
Acalabrutinib in patients with CLL and MCL undergoing alloSCT
Wojciech Jurczak • 11 Jun 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals